Protozoan parasites lack de novo purine biosynthesis and require purin
e salvage from the host. Nucleoside hydrolases are involved in nucleos
ide salvage and are not found in mammals, making them protozoan-specif
ic targets for inhibitor design. Several protozoan nucleoside hydrolas
e isozymes with distinct substrate specificities have been characteriz
ed. Novel substituted iminoribitols have been synthesized to resemble
the transition state structure of the nonspecific inosine-uridine nucl
eoside hydrolase from Crithidia fasciculata (IU-nucleoside hydrolase).
These inhibitors have been characterized for this enzyme and for a pu
rine-specific nucleoside hydrolase (IAC-nucleoside hydrolase) from Try
panosoma brucei brucei. Inhibitors which provide nanomolar inhibition
constants for IU-nucleoside hydrolase exhibit micromolar inhibition co
nstants for the IAG-enzyme. For example, p-bromophenyliminoribitol inh
ibits the IU- and IAG-enzymes with dissociation constants of 28 nM and
190 mu M, respectively. Substrate specificity, the action of transiti
on state inhibitors and the pH-dependence of the kinetic constants est
ablish that the catalytic mechanisms and transition state structures a
re fundamentally different for the IU- and IAG-isozymes. The finding i
s remarkable since these isozymes share significant homology at the ca
talytic sites and both use inosine as a preferred substrate. The speci
ficity of the transition state analogues indicates that logically-desi
gned transition state inhibitors are isozyme specific, with (K-m/K-i I
U-nucleoside hydrolase)/ (K-m/K-i IAG-nucleoside hydrolase) values up
to 39 000. The mechanism of the differential inhibition is based on th
e relative leaving group activation and ribosyl-oxocarbenium-forming a
bilities of these enzymes. In addition to providing isozyme-specific i
nhibitors, the novel molecules described here have diagnostic value fo
r the nature of the transition states for N-ribohydrolase enzymes.